Table 4.

Baseline evaluations before anti-CD20 treatment to assess infective risk

1. General assessment

• Review vaccination record • Review past medical history • Review concurrent drug history • Review travel history

2. Investigations

• Complete blood count • Immunoglobulin G, A, M • G6PD status (for use of cotrimoxazole as PJP prophylaxis) • Screening for Mycobacterium tuberculosis infection - Tuberculin skin test (TST) - Interferon gamma release assay (IGRA) • Serologic testing for (a) Hepatitis B virus (HBV) - Hepatitis B core antibody total (anti-HBc total) - Hepatitis B surface antibody (anti-HBs) - Hepatitis B virus surface antigen (HbsAg) - HBV DNA in HBsAg-positive patients (b) Hepatitis C virus (anti-HCV IgG) (c) Cytomegalovirus (CMV IgG) (d) Epstein-Barr virus (EBV IgG) (e) Human Immunodeficiency Virus (fourth-generation antigen/antibody combination test) (f) Varicella-zoster virus (VZV IgG) (g) Measles, mumps, rubella, if available • Optional: - B-cell subsets - Chest radiograph (to rule out active infection or in case of positive TB screening in high prevalence areas)